We were tasked with rebranding a new medicine that hit the market - Solovecin - for Dechra Pharmaceuticals, a leading veterinary pharmaceutical company, and developing a fully integrated campaign to differentiate it within the crowded canine pain management category. Rather than focusing solely on clinical claims, we repositioned the brand around restoring dogs to their true selves, shifting the narrative from treatment to transformation. The new identity embraced warmer visuals, movement-driven design elements, and more emotional storytelling, supported by a scalable campaign platform that extended across in-clinic materials, digital, and social touchpoints.